Intra-Cellular Therapies Inc. has patented compounds acting as serotonin transporter (SERT), 5-HT2A, dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.
Easymotionskin Tec AG is seeking patent protection for a wearable product that delivers transcutaneous electromyostimulation (EMS) of pelvic floor musculature through the body’s perineum, for the non-invasive treatment of incontinence, particularly stress incontinence. The invention is said to be suited to nearly all patients, including those patients who cannot insert anal or vaginal probes that provide pelvic floor training by EMS.
Guangzhou Maxinovel Pharmaceuticals Co. Ltd. has described thienopyrimidine compounds acting as ALK, fibroblast growth factor receptor (FGFR) and high affinity nerve growth factor (TRK) inhibitors reported to be useful for the treatment of cancer, infections and psoriasis and inflammation.
Nammi Therapeutics Inc. has divulged prodrugs of Toll-like receptor (TLR) agonists and its self-assembled lipid nanoparticles reported to be useful for the treatment of cancer and immunological disorders.
Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.
JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
The U.S. Court of Appeals for the Federal Circuit has once again ruled on a patent dispute between Masimo Corp., of Irvine, Calif., and a rival firm, this time with Sotera Wireless Inc., of San Diego serving as the adversary. The Federal Circuit sided with Sotera in decreeing that 17 claims in Masimo’s RE47,218 (the ’218 patent) are invalidated due to the existence of prior art that rendered the claims obvious, but the irony in this litigation is that one of the patents cited by Sotera as prior art, the 6,597,933 patent, was authored in part by Joe Kiani, the founder, CEO and board chairman of Masimo.
Connex Biomedical Inc. applied for patent protection for a transcardiac access port affixed and retained post-procedure on the cardiac muscle, such as the ventricular myocardium, and an access port delivery system configured to deliver the access port, secure the access port to the muscle tissue with tissue anchors, and provide a working channel through the access port to facilitate transcardiac access and device delivery.
Merck Sharp & Dohme Ltd. has described ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors reported to be useful for the treatment of cancer, Lewy body dementia, diabetes, obesity, polycystic kidney disease, neurodegeneration, lysosomal storage disease and Parkinson’s disease, among others.
RSS
